Systemic and Topical CMV Eye Infection: Treatment Outcomes
Official title: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: TreatmentOutcomes (STACCATO)
Funded at University of California, San Francisco · NIH-11264266 · Data updated 2026-11-12
A study to find the best way to treat CMV anterior uveitis, a serious eye infection that can cause blindness, using oral antiviral drugs, eye drops, or observation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 15, 2026 |
| Project end | January 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $542,815 |
| NIH project number | 1UG1EY036344-01A1 |
| Project ID | NIH-11264266 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with CMV-associated anterior uveitis or at high risk for CMV anterior uveitis who require diagnostic confirmation and treatment planning.
✕Less likely to help
Patients with CMV anterior uveitis who respond equally to current standard care or who do not require antiviral therapy may see limited benefit.
What this research studies
Cytomegalovirus anterior uveitis causes significant eye inflammation and can lead to glaucoma or corneal damage. This project compares systemic oral valganciclovir, topical ganciclovir eye drops, and observation to determine which approach provides the best outcomes for patients. The research involves diagnosis through anterior chamber sampling and monitoring treatment safety, side effects, and disease control over time. Results could guide clinicians in choosing effective, safer, and more affordable options for people affected by CMV-related eye disease.
Why it matters
Potential benefit: If successful, patients could receive more effective and safer treatment options for CMV anterior uveitis, potentially reducing vision loss.
How similar studies have gone: Previous observational data suggest antiviral approaches can control CMV eye disease, but robust randomized trials are needed and this study addresses that gap.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gonzales, John Alexander — University of California, San Francisco
- Study coordinator: Gonzales, John Alexander
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.